| Original language | English |
|---|---|
| Pages (from-to) | 1634-1635 |
| Number of pages | 2 |
| Journal | European Heart Journal |
| Volume | 40 |
| Issue number | 25 |
| DOIs | |
| State | Published - 1 Jul 2019 |
Bibliographical note
Funding Information:The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells (BM-MNC) on All Cause Mortality in Acute Myocardial Infarction (BAMI) study is funded by a E5.9 m European Commission award and will involve 19 partners in 10 European countries.
Funding Information:
The REGENERATE (Heart Stem Cell) Trial at Barts Health NHS Trust is being led by Professor Anthony Mathur and is made up of three randomized, controlled studies funded by the Heart Cells Foundation (HCF), the UK Stem Cell Foundation and Barts Charity. It has seen patients’ own stem cells injected directly into the heart to promote tissue regeneration. The Phase 2 trials have focussed on three separate groups: patients who have just had a myocardial infarction; patients with ongoing heart failure; and those with dilated cardiomyopathy.
Funding
The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells (BM-MNC) on All Cause Mortality in Acute Myocardial Infarction (BAMI) study is funded by a E5.9 m European Commission award and will involve 19 partners in 10 European countries. The REGENERATE (Heart Stem Cell) Trial at Barts Health NHS Trust is being led by Professor Anthony Mathur and is made up of three randomized, controlled studies funded by the Heart Cells Foundation (HCF), the UK Stem Cell Foundation and Barts Charity. It has seen patients’ own stem cells injected directly into the heart to promote tissue regeneration. The Phase 2 trials have focussed on three separate groups: patients who have just had a myocardial infarction; patients with ongoing heart failure; and those with dilated cardiomyopathy.
| Funders |
|---|
| BM-MNC |
| Heart Cells Foundation |
| UK Stem Cell Foundation |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver